Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
•
Oncology
What criteria are used to select patients who have locally advanced BCC patients for treatment with sonidegib? What treatment combinations be used to maximize results?
Related Questions
After achieving clinical response to bexarotene for cutaneous lymphoma (e.g., MF stage Ib or FMF), do you wean to the lowest dose for sustained remission, and if so, when?
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
When do you recommend SRT, if ever, for small SCCs and BCCs?
Have you considered intralesional cempilumab for locally advanced NMSC/KCs prior to surgery?
Would you offer adjuvant immunotherapy in an elderly patient with stage IIB desmoplastic melanoma post resection with underlying autoimmune disease?
How would you manage a scalp squamous cell carcinoma s/p Mohs with high risk features who underwent placental grafting to expedite the healing process?
What patient characteristics or clinical scenarios guide the decision in performing slow Mohs procedures?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
What is your experience with itraconazole as a primary or adjunct therapy for individuals with numerous BCCs?
What is your preferred treatment for actinic cheilitis?
